Jun 2026 (Q2 FY26) — Aug 6, 2026
Zai Lab Q2 FY26 — Pipeline Advancement and Commercial Profitability
Read the full callZai Lab (ZLAB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Zai Lab earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 106 | −3.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -72.0 | −22.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -50.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$24.06 +3.75% · +$0.87
Performance −15.0% 1Y
1Y: $28.29 on 17 Oct 2025 → $24.06. High $29.15 (21 Oct 2025), low $16.3 (2 Feb 2026).
- Previous close
- $23.19
- 52-week range
- $16.3 – $29.15
- One year
- −16.28%
Overview
- Symbol
- ZLAB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Zai Lab earnings calls (ZLAB)
Financials
What the filings say
Net profit, year on year: −25% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 109 | 106 | 110 | 116 | 128 | 100 | 106 |
| Operating profit | -68 | -68 | -56 | -55 | -49 | -69 | -69 | -76 |
| Operating margin | −66.3% | −62.3% | −52.9% | −49.9% | −42.0% | −54.4% | −69.7% | −72.0% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -42 | -82 | -48 | -41 | -36 | -53 | -50 | -52 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.5% | −2.9% | 2.0% |
| Net profit | -42 | -82 | -48 | -41 | -36 | -50 | -51 | -51 |
| EPS ($ per share) | -0.04 | — | -0.04 | -0.04 | -0.03 | — | -0.05 | -0.05 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -250 | -445 | -714 | -1,418 | -1,861 | -2,196 | -2,453 | -2,629 |
| Total liabilities | 51 | 60 | 128 | 230 | 175 | 240 | 345 | 457 |
| Fixed assets | 20 | 21 | 29 | 43 | 58 | 54 | 48 | 47 |
| Investments | 200 | 200 | 745 | 445 | 0 | 16 | 330 | 10 |
| Total assets | 302 | 355 | 1,298 | 1,610 | 1,220 | 1,036 | 1,186 | 1,172 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -98 | -191 | -216 | -549 | -368 | -198 | -215 | -151 |
| Cash from investing | -213 | -15 | -555 | 250 | 420 | -11 | -375 | 308 |
| Cash from financing | 144 | 219 | 1,132 | 820 | -2 | -6 | 350 | 72 |
| Net cash flow | -167 | 13 | 366 | 522 | 44 | -218 | -240 | 230 |
| Capital expenditure | -10 | -6 | -10 | -18 | -25 | -7 | -6 | -8 |
| Free cash flow | -108 | -197 | -226 | -568 | -392 | -205 | -221 | -159 |
Insider filings
100 filings between Oct 31, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
$65.8K
2 purchases by 1 insider
Sales
$11.12M
40 sales by 6 insiders
50% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 8
- Award — granted as compensation
- 39
- Option exercise — converted options into shares
- 6
- Tax withheld — shares kept back by the company to cover tax
Also filed: 5 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Du Ying | — | $8.58M | Jun 30, 2026 |
| Edmondson Frazor Titus III | — | $1.01M | Jun 26, 2026 |
| Amado Rafael | — | $675.0K | Apr 6, 2026 |
| Lis William | — | $340.0K | Aug 12, 2026 |
| Smiley Joshua L | — | $294.3K | Apr 6, 2026 |
| Chen Yajing | — | $223.6K | Aug 19, 2026 |
| GAYNOR RICHARD | $65.8K | — | Jul 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Chen Yajing Chief Financial Officer | Tax withheld | 315 | $8.0K |
| Oct 1, 2026 | Chen Yajing Chief Financial Officer | Option exercise | 920 | — |
| Aug 19, 2026 | Chen Yajing Chief Financial Officer | Sale 10b5-1 plan | 260 | $7.0K |
| Aug 14, 2026 | Chen Yajing Chief Financial Officer | Tax withheld | 427 | $11.1K |
| Aug 14, 2026 | Chen Yajing Chief Financial Officer | Option exercise | 1,250 | — |
| Aug 12, 2026 | Lis William Director | Sale 10b5-1 plan | 8,506 | $212.7K |
| Aug 11, 2026 | Chen Yajing Chief Financial Officer | Sale 10b5-1 plan | 619 | $15.5K |
| Jul 2, 2026 | Du Ying Chairperson & CEO | Option exercise | 11,048 | — |
| Jul 2, 2026 | Du Ying Chairperson & CEO | Tax withheld | 4,348 | $83.1K |
| Jul 1, 2026 | Du Ying Chairperson & CEO | Tax withheld | 7,083 | $135.6K |
| Jul 1, 2026 | GAYNOR RICHARD Director | Purchase 10b5-1 plan | 1,736 | $33.1K |
| Jul 1, 2026 | Du Ying Chairperson & CEO | Option exercise | 18,000 | — |
| Jun 30, 2026 | Du Ying Chairperson & CEO | Sale | 7,026 | $130.2K |
| Jun 29, 2026 | Du Ying Chairperson & CEO | Option exercise | 17,970 | — |
| Jun 26, 2026 | Chen Yajing Chief Financial Officer | Sale | 2,264 | $39.5K |
| Jun 26, 2026 | Edmondson Frazor Titus III Chief Legal Officer | Sale | 4,103 | $71.6K |
| Jun 26, 2026 | Du Ying Chairperson & CEO | Sale | 24,543 | $428.5K |
| Jun 25, 2026 | Du Ying Chairperson & CEO | Option exercise | 58,800 | — |
| Jun 25, 2026 | Chen Yajing Chief Financial Officer | Option exercise | 6,250 | — |
| Jun 25, 2026 | Edmondson Frazor Titus III Chief Legal Officer | Option exercise | 14,600 | — |
| Jun 22, 2026 | Lis William Director | Sale 10b5-1 plan | 7,040 | $127.4K |
| Jun 17, 2026 | Morrison Scott W Director | Award | 22,371 | $0 |
| Jun 17, 2026 | DIEKMAN JOHN D Director | Award | 22,371 | $0 |
| Jun 17, 2026 | GAYNOR RICHARD Director | Award | 22,371 | $0 |
| Jun 17, 2026 | Lis William Director | Award | 22,371 | $0 |
| Jun 17, 2026 | WIRTH PETER Director | Award | 22,371 | $0 |
| Jun 17, 2026 | Vounatsos Michel Director | Award | 22,371 | $0 |
| Jun 17, 2026 | Leung Nisa Director | Award | 22,371 | $0 |
| Jun 17, 2026 | MOULDER LEON O JR Director | Award | 22,371 | $0 |
| May 27, 2026 | Du Ying Chairperson & CEO | Gift | 53,850 | $0 |
| May 27, 2026 | Du Ying Chairperson & CEO | Gift | 33,993 | $0 |
| May 26, 2026 | Du Ying Chairperson & CEO | Gift | 19,857 | $0 |
| May 19, 2026 | Du Ying Chairperson & CEO | Tax withheld 10b5-1 plan | 117,435 | $2.20M |
| May 19, 2026 | Du Ying Chairperson & CEO | Option exercise 10b5-1 plan | 261,092 | $454.3K |
| May 18, 2026 | Du Ying Chairperson & CEO | Option exercise 10b5-1 plan | 50,000 | $87.0K |
| May 18, 2026 | Du Ying Chairperson & CEO | Sale 10b5-1 plan | 50,000 | $949.8K |
| May 15, 2026 | Du Ying Chairperson & CEO | Sale 10b5-1 plan | 50,000 | $1.04M |
| May 15, 2026 | Du Ying Chairperson & CEO | Option exercise 10b5-1 plan | 50,000 | $87.0K |
| May 14, 2026 | Edmondson Frazor Titus III Chief Legal Officer | Sale 10b5-1 plan | 3,517 | $71.0K |
| May 14, 2026 | Du Ying Chairperson & CEO | Sale 10b5-1 plan | 50,000 | $1.00M |
| May 14, 2026 | Du Ying Chairperson & CEO | Option exercise 10b5-1 plan | 50,000 | $87.0K |
| May 13, 2026 | Du Ying Chairperson & CEO | Option exercise 10b5-1 plan | 50,000 | $87.0K |
| May 13, 2026 | Du Ying Chairperson & CEO | Sale 10b5-1 plan | 16,231 | $315.6K |
| May 13, 2026 | Du Ying Chairperson & CEO | Sale 10b5-1 plan | 33,769 | $682.9K |
| Apr 6, 2026 | Amado Rafael See Remarks | Sale | 2,739 | $56.0K |
| Apr 6, 2026 | Smiley Joshua L See Remarks | Sale | 3,017 | $61.7K |
| Apr 6, 2026 | Edmondson Frazor Titus III Chief Legal Officer | Sale | 1,224 | $25.0K |
| Apr 6, 2026 | Du Ying Chairperson & CEO | Sale | 2,653 | $54.2K |
| Apr 6, 2026 | Chen Yajing Chief Financial Officer | Sale | 853 | $17.4K |
| Apr 2, 2026 | Amado Rafael See Remarks | Sale | 9,910 | $202.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Zai Lab Ltd
Free account. Everything above stays public.
Write why you follow Zai Lab Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading